Drug intelligence / Profile preview

Mini ReCol

Development stage: Preclinical
Lead developer: 创健医疗
Modality: Recombinant Proteins and Enzymes
Administration: Topical, Transdermal

Overview

Mini ReCol is a recombinant collagen-based biomaterial developed by Chuangjian Medical (Trautec), specifically engineered for enhanced transdermal absorption and anti-aging applications. As a low-molecular-weight recombinant collagen fragment, it is designed to penetrate the skin barrier more effectively than traditional high-molecular-weight collagen. It functions by supplementing the skin's extracellular matrix, promoting cellular repair, and providing anti-wrinkle effects. It is primarily utilized as a high-performance ingredient in medical aesthetics and functional skincare products to improve skin elasticity and hydration.

Brand names: Mini ReColMini ReCol 3
Other names: Recombinant Collagen FragmentTrautec Recombinant Collagen

Beyond the preview

Go deeper on Mini ReCol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mini ReCol.

Explore the full profile